December 9, 2016

Here are brokerage firms’ views on 10 stocks

Biocon

Morgan Stanley is overweight with a raised target to Rs 1156 from Rs 889 per share  implying 30 percent upside. It has also increased FY17 & FY18 EPS estimates by 9 percent and 18 percent respectively. Expectinf monetisation cycle to begin next year onwards, it says that the company remains a multi-year growth and rerating story. The company is executing well on its bio similar pipeline in terms of US/EU filings.

Infosys

Infosys

CIMB maintains add rating on reasonable valuations with target cut to Rs 1185 from Rs 1250 per share. It has cut FY17-19 EPs by 2-3 percent on client- specific issues and weakening macro. It remains optimistic on medium-to-long term.

DLF

Deutsche Bank maintains hold rating on the stock. Its net sales bookings was at multi-year low but leasing slowed due to limited inventory. Cancellation exceeded new bookings for the 1st time since at least FY08. It says DLF’s commercial rental will remain robust . JP Morgan is overweight on the stock with target at Rs 175 per share as earnings was boosted by cinema business but pre-sales performance was muted.

BHEL

TradeIndia Research BHEL

JP Morgan is underweight on the stock with target cut to Rs 120 from Rs 125 per share. It says doubtful debtors increased and customer advances fell in FY16 while diversification beyond power has proved slow.

IOC

Bank of America Medill Lynch reiterated buy rating with target increased to Rs 680 per share. It has increased FY17 EPS by 18 percent stating that ramp-up of Paradip refinery is a positive. It cautions that weak refining run rate is a risk but volume upside supportive. Deutsche Bank  has a buy rating with  target at Rs 660 per share. It has raised FY17 EPS by 13 percebt to factor inventory gain.

Godrej Consumer

Nomura upgraded it to buy from neutral post recent correction with target increased to Rs 1765 from Rs 1630 per share. It says valuations at 32.5 FY18P/E seem reasonable.

JSW Energy

TradeIndia Research JSW

Nomura has cut earnings estimates on unfavorable interplay of macro variables with target price reduced to Rs 72 from Rs 79 per share. It warns of  an earnings hiccup ahead hence downgraded it to reduce.

Zee Entertainment

Macquarie has target price for stock at Rs 540 per share. Its hiving off sports business is positive on improved profitability and lower volatility. It says ZEE will see 400 BPS EBITDA margin expansion if deal closed for rs 2000 crore and will also see 10 percent EPS boost to FY18 financials if deal is sealed.

Bharat Financial

Morgan Stanley stays overweight with target price of Rs 925 per share.  It expects EPS CAGR of over 50 percent and ROE of over 25 percent in next 3 years. Its management emphasized that arrest of Dilliraj is unrelated to the company.

eClerx

CLSA downgraded it to sell from outperform but target remains unchanged. It says company missed revenue expectations sharply for the second quarter in a row and faced revenue headwinds from most large clients. Its drag from top 10 clients is likely to crimp full-year growth to low-single digits.

Free Stock Tips | Share Market Tips | Share Market Calls | Best Stock Advisory Company

Visit: http://www.tradeindiaresearch.com

Call: 7415033556

tradeindia on twitterstradeindia research facebook 100x100tradeindia research on linkedin100x100

TradeIndia Research is India's one of the best stock advisory who caters & delivers best stock recommendation in Share Market Tips. We also provide recommondation on Equity Tips, Commodity Tips and forex market.

TradeIndia1

Comments are closed.

NOTE : You are advised to take your position with your sense and judgment.The views and investment tips expressed by users on MCXStar.com are their own, and not that of the website or its management. MCXStar.com advises users to check with certified experts before taking any investment decisions. If any other company also giving same script and recommandation then we are not responsible for that. We have not any position in our given scripts. Visiting our web one should by agree to our terms and condition and disclaimer also. All credit goes to original authors of post on this website. Website owner is not responsible for any loss due to your own decision or judgement. Thanks for Visiting our Website.